Yue Wei, Ph.D.
Department of Leukemia, Division of Cancer Medicine
About Dr. Yue Wei
Dr. Wei is an assistant professor in the research group of Dr. Guillermo Garcia-Manero in the Department of Leukemia, University of Texas MD Anderson Cancer Center. The studies that she pursue on MDS and AML are under the mentorship of Dr. Guillermo Garcia-Manero, who is well known for his clinical achievement as well as his translational research in the field of leukemia and MDS. Dr. Wei has a PhD with over ten years of molecular and cellular research experience, she helps Dr. Garcia-Manero to design and to monitor research progress. She also has her own research interests concerning MDS/ AML, which is to characterize those molecules that are identified through clinical and translational studies, in basic research types of settings, including in vitro and in vivo biological models. Her goal is to figure out the physiological and pathological role of these molecules and their related molecular signals in hematopoiesis and in MDS/ AML pathogenesis. Her work will further contribute to clinical studies and treatment of MDS/ AML by providing information of potential prognostic markers and/ or therapeutic targets in these diseases.
Read More
Present Title & Affiliation
Primary Appointment
Associate Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2004 | Baylor College of Medicine, Houston, Texas, US, Ph.D. in Biophysics and Molecular Physiology |
Postgraduate Training
| 2004-2007 | Postdoctoral Research Associate, Cellular Biology, Baylor College of Medicine, Houston, Texas |
Honors & Awards
| 2013 | Junior Research Faculty Award, The University of Texas MD Anderson Cancer Center |
| 1998 | Graduated with Honor, Chinese Academy of Medical Sciences |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2023. Type-1 IFN Signaling in MDS & CMML. Invited. Leukemia Research Meeting. Houston, Texas, US.
- 2023. Targeting Innate Immunity Signaling in Myelodysplastic Syndrome. Invited. DoCM Grand Rounds. Houston, Texas, US.
- 2022. Inhibition of MDM2 in animal model of MDS and CMML. Invited. Leukemia Research Meeting. Houston, TX, US.
- 2020. Innate Immune Deregulation in MDS and CMML. Invited. Leukemia Research Meeting. Houston, Texas, US.
- 2019. ASH Review. Invited. Leukemia Research Meeting. Houston, TX, US.
- 2013. Activation of Innate Immunity in Myelodysplastic Syndrome (MDS). Invited. DoCM Grand Rounds Gerald P. Bodey Memorial Lecture. Houston, Texas, US.
- 2012. Deregulation of Innate Immunity Signaling and its Therapeutic Potential in Myelodysplastic Syndrome (MDS). Invited. DoCM Grand Rounds Gerald P. Bodey Memorial Lecture. Houston, Texas, US.
National Presentations
- 2019. KDM6B Overexpression and TET2 Deficiency Cooperatively Drive Development of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-like Phenotype in Mice. Conference. KDM6B Overexpression and TET2 Deficiency Cooperatively Drive Development of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-like Phenotype in Mice. Orlando, FL, US.
- 2017. Overexpression of Histone Demethylase KDM6B in the Hematopoietic Compartment Promotes the Effect of Innate Immune Activation and Results in Myelodysplastic Syndrome (MDS)-like Phenotype in Mice. Conference. Overexpression of Histone Demethylase KDM6B in the Hematopoietic Compartment Promotes the Effect of Innate Immune Activation and Results in Myelodysplastic Syndrome (MDS)-like Phenotype in Mice. Atlanta, GA, US.
- 2013. Role of Innate Immunity in Myelodysplastic Syndrome (MDS). Invited. SOHO. Houston, TX, US.
- 2013. Targeting Innate Immunity Signaling in Myelodysplastic Syndrome (MDS). Invited. Edward P. Evans Foundation MDS. New York, New York, US.
- 2012. Toll-Like Receptor (TLR) Signaling Adaptor Protein MYD88 in Myelodysplastic Syndromes (MDS). Conference. Toll-Like Receptor (TLR) Signaling Adaptor Protein MYD88 in Myelodysplastic Syndromes (MDS). San Francisco, CA, US.
- 2011. Innate Response/Inflammation. Conference. University of Minnesota and Knowledge Oncology, LLC. Houston, TX, US.
- 2010. Analysis of Regulatory miRNAs of Histone Demethylase JMJD3 in MDS CD34+ Hematoprogenitor Cells. Conference. Analysis of Regulatory miRNAs of Histone Demethylase JMJD3 in MDS CD34+ Hematoprogenitor Cells. Orlando, FL, US.
- 2010. Histone Code Alterations in MDS. Conference. University of Minnesota and Knowledge Oncology, LLC. Houston, TX, US.
- 2010. Genome-wide CHIP-Seq analysis of histone methylation reveals modulators of NF-κB signaling and the histone demethylase JMJD3 as implicated in disease progression in myelodysplastic syndrome (MDS). Conference. Genome-wide CHIP-Seq analysis of histone methylation reveals modulators of NF-κB signaling and the histone demethylase JMJD3 as implicated in disease progression in myelodysplastic syndrome (MDS). Washington, DC, US.
- 2009. Genome-Wide Chip-Seq Analysis of Histone Methylation Reveals Modulators of NF-κB Signaling and the Histone Demethylase JMJD3 as Implicated in Disease Progression in Myelodysplastic Syndrome (MDS). Conference. Genome-Wide Chip-Seq Analysis of Histone Methylation Reveals Modulators of NF-κB Signaling and the Histone Demethylase JMJD3 as Implicated in Disease Progression in Myelodysplastic Syndrome (MDS). New Orleans, LA, US.
- 2009. Histone Code Alterations in MDS. Conference. University of Minnesota and KnowledgeOncology, LLC. Houston, TX, US.
Grant & Contract Support
| Date: | 2025 - 2032 |
| Title: | PRECLINICAL EVALUATION OF PIM-1 KINASE INHIBITOR TP3654 IN MDS AND CMML |
| Funding Source: | Sumitomo Pharma Oncology, Inc |
| Role: | Co-PI |
| ID: | RCTS# 65425 |
| Date: | 2025 - Present |
| Title: | Dissecting cell-type composition, tissue cartography and RAS signal dependency to overcome disease progression and tissue infiltration in chronic myelomonocytic leukemia |
| Funding Source: | The University of Texas - MD Anderson Cancer Center |
| Role: | Key |
| Date: | 2025 - 2027 |
| Title: | PA19-0345 Clonal Hematopoiesis (CH), Myelodysplastic Syndromes (MDS), and Chronic Myelomonocytic Leukemia (CMML) - MENIN INHIBITOR |
| Funding Source: | Sumitomo |
| Role: | Co-PI |
| ID: | RCTS# 64738 |
| Date: | 2024 - 2025 |
| Title: | Dissecting Molecular Mechanisms underlying Megakaryo-Response in Hypomethylation Therapy of Myelodysplastic Syndrome |
| Funding Source: | When Everyone Survives Foundation |
| Role: | PI |
| ID: | FP00023083 |
| Date: | 2024 - 2026 |
| Title: | Evaluating the therapeutic potential of CCR2-directed Cytotoxicity in Chronic Myelomonocytic Leukemia and Acute Myelomonocytic Leukemia |
| Funding Source: | Solu Pharma |
| Role: | Co-PI |
| ID: | AWD00008169 |
| Date: | 2023 - 2025 |
| Title: | Dissecting UBA1 Dysregulation in MDS |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
| ID: | 62990 |
| Date: | 2021 - 2028 |
| Title: | Targeting innate immune deregulation in Myelodysplastic syndromes and Chronic Myelomonocytic Leukemia via IRAK1/4 Inhibition |
| Funding Source: | Rigel Pharmaceutical |
| Role: | Co-I |
| ID: | AWD00005698 |
| Date: | 2020 - 2025 |
| Title: | Study the role of STING activation in MDS/CMML |
| Funding Source: | Takeda Pharmaceutical |
| Role: | Co-PI |
| ID: | 60473 |
| Date: | 2020 - 2025 |
| Title: | Study of p38MAPK inhibition in MDS/CMML mouse models & in primary patient bone marrow cells |
| Funding Source: | Pfizer/Array Pharmaceutical |
| Role: | Co-PI |
| Date: | 2020 - 2021 |
| Title: | Dissecting Biological Signatures and Therapeutic Targets of Hypomethylation Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia |
| Funding Source: | WES Foundation |
| Role: | PI |
| Date: | 2020 - 2021 |
| Title: | Investigating the Biology and Therapeutic Potential of the Interactions between Innate Immune Deregulation and Frequent Genetic Mutations in Myelodysplastic Syndromes |
| Funding Source: | Leukemia Texas |
| Role: | PI |
| Date: | 2019 - 2021 |
| Title: | Dissecting pathogenic cooperation between KDM6B overexpression and TET2 loss in bone marrow failure |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| Date: | 2019 - 2024 |
| Title: | PA15-0926: Targeting innate immune deregulation in MDS via MDM2 inhibition |
| Funding Source: | Daiichi Sankyo Co Ltd |
| Role: | Principal Investigator-MDACC |
| Date: | 2019 - 2022 |
| Title: | TET2 loss cooperates with innate immune deregulation in MDS/CMML pathogenesis and HMA resistance |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | PI |
| Date: | 2019 - 2020 |
| Title: | Identification and inhibition of molecular innate immune signature in HMA failure of MDS and CMML |
| Funding Source: | Ladies Leukemia League |
| Role: | PI |
| Date: | 2019 - 2021 |
| Title: | Modeling KDM6B overexpression in myelodysplastic syndrome |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2018 - 2019 |
| Title: | Characterize Pathologic Interactions Between KDM6B Overexpression and TET2 Loss in MDS |
| Funding Source: | UTMDACC Leukemia SPORE Development Award |
| Role: | PI |
| Date: | 2018 - 2020 |
| Title: | Histone demethylase KDM6B in myelodysplastic syndrome (MDS): |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2018 - 2020 |
| Title: | Histone demethylase KDM6B in myelodysplastic syndrome (MDS): pathological role and |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1 R21 CA231578-01 |
| Date: | 2018 - 2019 |
| Title: | Characterize the pathological and therapeutic potential of histone demethylase KDM6B in MDS |
| Funding Source: | Leukemia Research Foundation |
| Role: | PI |
| Date: | 2018 - 2019 |
| Title: | Characterizing KDM6B targeting as a novel therapeutic target in myelodysplastic syndrome |
| Funding Source: | MD Anderson Institutional Research Grant |
| Role: | PI |
| Date: | 2017 - 2019 |
| Title: | Characterizing KDM6B as a novel therapeutic target in myeloid neoplasms |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R03CA215831-01 |
| Date: | 2014 - 2017 |
| Title: | Targeting TollL-Like Receptor and Innate Immunity Signaling in Hypomethylating Failure MDS |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | PI |
| Date: | 2014 - 2017 |
| Title: | Towards the cure of myelodysplastic syndrome: interfering with innate immunity alterations in human and mouse systems |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| ID: | RP140500 |
| Date: | 2014 - 2019 |
| Title: | Biology of MDS |
| Funding Source: | NIH/NHLBI |
| Role: | Co-Investigator, Project 3 |
| ID: | 1P01HL117793-01 |
| Date: | 2013 - 2016 |
| Title: | Role of deregulated innate immunity signaling in resistance to hypomethylating agent based therapy in myelodysplastic syndrome and acute myelogenous leukemia |
| Funding Source: | Gabrielle's Angel Foundation |
| Role: | PI |
| Date: | 2013 - 2018 |
| Title: | MDS/AML Moon Shot |
| Funding Source: | The University of Texas MD Anderson Cancer Center Moon Shot Program |
| Role: | Co-I |
| Date: | 2013 - 2017 |
| Title: | Effect of Innate Immune Signal Deregulation and Telomere Dysfunction in Myelodysplastic Syndrome and Aging |
| Funding Source: | Ellison Medical Foundation |
| Role: | PI |
| Date: | 2013 - 2015 |
| Title: | Interaction of Dysregulated Innate Immunity Signal and Telomere Integrity in Myelodysplastic Syndrome |
| Funding Source: | Aplastic Anemia & MDS International Foundation |
| Role: | PI |
| Date: | 2013 - 2018 |
| Title: | MDS Clinical Research Consortium |
| Funding Source: | Aplastic Anemia & MDS Intl Foundation |
| Role: | Program Leader |
| ID: | 13045729 |
| Date: | 2013 - 2016 |
| Title: | Targeting the histone demethylase JMJD3 and innate immunity deregulation in myelodysplastic syndromes |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP130080 |
| Date: | 2013 - 2014 |
| Title: | A randomized clinical trial for patients with AML/MDS not fit for chemotherapy |
| Funding Source: | American Society of Hematology (ASH) |
| Role: | Co-I |
| Date: | 2013 - 2018 |
| Title: | Innate Immunity Alterations in MDS |
| Funding Source: | NIH/NHLBI |
| Role: | Co-I |
| ID: | 1R01HL118107-01 |
| Date: | 2013 - 2014 |
| Title: | E. P. Evans Fellowship |
| Funding Source: | Aplastic Anemia & MDS International Foundation supported by the Evans Foundation |
| Role: | PI |
| Date: | 2012 - 2015 |
| Title: | Targeting of an Innate Immunity-like Pathway in Myelodysplastic Syndrome |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Co-I |
| Date: | 2012 - 2015 |
| Title: | CA110791: Innate immunity dysregulation in myelodysplastic syndromes |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | W81XWH-12-1-0221 |
| Date: | 2012 - 2017 |
| Title: | A randomized clinical trial for patients with AML/MDS not fit for Chemotherapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | GRANT10976413 |
| Date: | 2012 - 2014 |
| Title: | Targeting innate immunity alterations in myelodysplastic syndrome (PQ20) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R21 |
| Date: | 2012 - 2017 |
| Title: | Aberrant DNA Methylation as a Mechanism of Resistance in Acute Lymphocytic Leukemia (ALL) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 10712701 |
| Date: | 2010 - 2013 |
| Title: | Career Development Award of Leukemia Spore "Modulation of IL6-JMJD3 signaling pathway in myelodysplastic syndromes (MDS)" |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| ID: | 2P50 CA100632-08 |
| Date: | 2010 - 2013 |
| Title: | Analysis of histone code alterations and JMJD3 using CHIP-seq in myelodysplastic syndromes |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| ID: | RP101320 |
| Date: | 2010 - 2011 |
| Title: | Career Development Award of Leukemia SPORE "Analysis of regulatory miRNAs of histone demethylase JMJD3 in MDS CD34+ progenitors" |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| ID: | 2P50 CA100632-08 |
| Title: | Dissecting Biological Signatures and Therapeutic Targets of Hypomethylation Agent Resistance in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Bazinet, A, Loghavi, S, Wei, Y, Bataller Torralba, A, Sasaki, K, Arani, N, Darbaniyan, F, Chien, KS, Hammond, DE, Bouligny, IM, Kanagal Shamanna, R, Thongon, N, Tang, G, Urrutia, S, Kadia, TM, DiNardo, C, Daver, N, Short, NJ, Issa, GC, Pemmaraju, N, Jabbour, EJ, Wang, S, Wang, W, Borthakur, G, Bueso-Ramos, CE, Ravandi-Kashani, F, Medeiros, LJ, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy. Leukemia 39(9):2256-2265, 2025. e-Pub 2025. PMID: 40691503.
- Wei Y, Hong Zheng, Pamela Lockyer, Faezeh Darbaniyan, Rashmi Kanagal-Shamanna, Hui Yang, Danielle Hammond, Guillermo Garcia Manero. Downregulation of UBA1 in Myelodysplastic Syndrome. Leukemia. e-Pub 2024.
- Wei Y, Zheng H, Lockyer PP, Darbaniyan F, Li Z, Kanagal-Shamanna R, Soltysiak KA, Yang H, Ganan-Gomez I, Montalban-Bravo G, Chien KS, Do KA, Daver N, Garcia-Manero G. MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 63(13):3154-3164, 2022. e-Pub 2022. PMID: 36059252.
- Darbaniyan F, Zheng H, Kanagal-Shamanna R, Lockyer P, Montalban-Bravo G, Estecio M, Lu Y, Soltysiak KA, Chien KS, Yang H, Sasaki K, Class C, Ganan-Gomez I, Do KA, Garcia-Manero G, Wei Y. Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Exp Hematol 115:44-53, 2022. e-Pub 2022. PMID: 36150563.
- Yang H, Garcia-Manero G, Sasaki K, Montalban-Bravo G, Tang Z, Wei Y, Kadia T, Chien K, Rush D, Nguyen H, Kalia A, Nimmakayalu M, Bueso-Ramos C, Kantarjian H, Medeiros LJ, Luthra R, Kanagal-Shamanna R. High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance. Leukemia 36(9):2306-2316, 2022. e-Pub 2022. PMID: 35915143.
- Wei Y, Kanagal-Shamanna R, Zheng H, Bao N, Lockyer PP, Class CA, Darbaniyan F, Lu Y, Lin K, Yang H, Montalban-Bravo G, Ganan-Gomez I, Soltysiak KA, Do KA, Colla S, Garcia-Manero G. Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. Leukemia 36(8):2097-2107, 2022. e-Pub 2022. PMID: 35697791.
- Li J, Hong T, Wei Y, Guo L, Lee M, Yang H, Class C, Yang Y, Wang X, He H, Siwko S, You MJ, Zhou Y, Garcia-Manero G, Huang Y. Aberrant DNA hydroxymethylation reshapes transcription factor binding in myeloid neoplasms. Clin Epigenetics 14(1):81, 2022. e-Pub 2022. PMID: 35765052.
- Kanagal-Shamanna R, Montalban-Bravo G, Sasaki K, Darbaniyan F, Jabbour E, Bueso-Ramos C, Wei Y, Chien K, Kadia T, Ravandi F, Borthakur G, Soltysiak KA, Routbort M, Patel K, Pierce S, Medeiros LJ, Kantarjian HM, Garcia-Manero G. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer 127(19):3552-3565, 2021. e-Pub 2021. PMID: 34161603.
- Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, Daver N, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol 96(7):E246-E249, 2021. e-Pub 2021. PMID: 33811786.
- Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J 11(3):52, 2021. e-Pub 2021. PMID: 33677472.
- Montalban-Bravo G, Darbaniyan F, Kanagal-Shamanna R, Ganan-Gomez I, Class CA, Sasaki K, Naqvi K, Wei Y, Yang H, Soltysiak KA, Chien KS, Bueso-Ramos C, Do KA, Kantarjian H, Garcia-Manero G. Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. Leuk Res 101:106511, 2021. e-Pub 2021. PMID: 33517186.
- Chien KS, Class CA, Montalban-Bravo G, Wei Y, Sasaki K, Naqvi K, Ganan-Gomez I, Yang H, Soltysiak KA, Kanagal-Shamanna R, Do KA, Kantarjian HM, Garcia-Manero G. LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. Leuk Lymphoma 61(6):1493-1499, 2020. e-Pub 2020. PMID: 32036728.
- Montalban-Bravo G, Class CA, Ganan-Gomez I, Kanagal-Shamanna R, Sasaki K, Richard-Carpentier G, Naqvi K, Wei Y, Yang H, Soltysiak KA, Chien K, Bueso-Ramos C, Do KA, Kantarjian H, Garcia-Manero G. Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. Leukemia 34(3):872-881, 2020. e-Pub 2020. PMID: 31719677.
- Chekouo T, Stingo FC, Class CA, Yan Y, Bohannan Z, Wei Y, Garcia-Manero G, Hanash S, Do KA. Investigating protein patterns in human leukemia cell line experiments: A Bayesian approach for extremely small sample sizes. Stat Methods Med Res:962280219852721. e-Pub 2019. PMID: 31172886.
- Wei Y, Zheng H, Bao N, Jiang S, Bueso-Ramos CE, Khoury J, Class C, Lu Y, Lin K, Yang H, Ganan-Gomez I, Starczynowski DT, Do KA, Colla S, Garcia-Manero G. KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. Blood Adv 2(19):2491-2504, 2018. e-Pub 2018. PMID: 30275007.
- Abaza Y, Hidalgo-Lopez JE, Verstovsek S, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Alvarado Y, Burger J, Schneider H, Soltysiak KA, Wei Y, Kantarjian HM, Bueso-Ramos CE, Garcia-Manero G. Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res 73:78-85, 2018. e-Pub 2018. PMID: 30245189.
- Zhang H, Li HS, Hillmer EJ, Zhao Y, Chrisikos TT, Hu H, Wu X, Thompson EJ, Clise-Dwyer K, Millerchip KA, Wei Y, Puebla-Osorio N, Kaushik S, Santos MA, Wang B, Garcia-Manero G, Wang J, Sun SC, Watowich SS. Genetic rescue of lineage-balanced blood cell production reveals a crucial role for STAT3 antiinflammatory activity in hematopoiesis. Proc Natl Acad Sci U S A. e-Pub 2018. PMID: 29463696.
- Yang H, Fang Z, Wei Y, Bohannan ZS, Gañán-Gómez I, Pierola AA, Paradiso LJ, Iwamura H, Garcia-Manero G. Preclinical activity of FF-10501-01, a novel inosine-5'-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia. Leuk Res 59:85-92, 2017. e-Pub 2017. PMID: 28599189.
- Daher M, Hidalgo Lopez JE, Randhawa JK, Jabbar KJ, Wei Y, Pemmaraju N, Borthakur G, Kadia T, Konopleva M, Kantarjian HM, Hearn K, Estrov Z, Reyes S, Bueso-Ramos CE, Garcia-Manero G. An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. Am J Hematol 92(7):674-682, 2017. e-Pub 2017. PMID: 28370157.
- Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G. Impact of Achievement of Complete Cytogenetic Response on Outcome in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents. Am J Hematol 92(4):351-358, 2017. e-Pub 2017. PMID: 28076892.
- Chamseddine AN, Cabrero M, Wei Y, Ganan-Gomez I, Colla S, Takahashi K, Yang H, Bohannan ZS, Garcia-Manero G. PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Clin Lymphoma Myeloma Leuk 16 Suppl:S67-73, 2016. e-Pub 2016. PMID: 27521329.
- Cabrero M, Wei Y, Yang H, Ganan-Gomez I, Bohannan Z, Colla S, Marchesini M, Bravo GM, Takahashi K, Bueso-Ramos C, Garcia-Manero G. Down-regulation of EZH2 expression in myelodysplastic syndromes. Leuk Res 44:1-7, 2016. e-Pub 2016. PMID: 26970171.
- Cabrero M, Yu Y, Verma A, Yang H, Colla S, Jia Y, Zheng H, Bohannan Z, Ganan-Gomez I, Futreal A, Takahashi K, Chin L, Kantarjian H, Pellagatti A, Bowman T, Boultwood J, Garcia-Manero G, Wei Y. Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. Br J Haematol 173(1):161-5, 2016. e-Pub 2016. PMID: 26105212.
- Zhang C, Suo J, Katayama H, Wei Y, Garcia-Manero G, Hanash S. Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines. Clin Proteomics 13:14, 2016. e-Pub 2016. PMID: 27382363.
- Yue W, Li Y, Zhang T, Jiang M, Qian Y, Zhang M, Sheng N, Feng S, Tang K, Yu X, Shu Y, Yue C, Jing N. ESC-Derived Basal Forebrain Cholinergic Neurons Ameliorate the Cognitive Symptoms Associated with Alzheimer's Disease in Mouse Models. Stem Cell Reports 5(5):776-90, 2015. e-Pub 2015. PMID: 26489896.
- Colla S, Ong DS, Ogoti Y, Marchesini M, Mistry NA, Clise-Dwyer K, Ang SA, Storti P, Viale A, Giuliani N, Ruisaard K, Ganan Gomez I, Bristow CA, Estecio M, Weksberg DC, Ho YW, Hu B, Genovese G, Pettazzoni P, Multani AS, Jiang S, Hua S, Ryan MC, Carugo A, Nezi L, Wei Y, Yang H, D'Anca M, Zhang L, Gaddis S, Gong T, Horner JW, Heffernan TP, Jones P, Cooper LJ, Liang H, Kantarjian H, Wang YA, Chin L, Bueso-Ramos C, Garcia-Manero G, DePinho RA. Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell 27(5):644-57, 2015. e-Pub 2015. PMID: 25965571.
- Estécio MR, Maddipoti S, Bueso-Ramos C, DiNardo CD, Yang H, Wei Y, Kondo K, Fang Z, Stevenson W, Chang KS, Pierce SA, Bohannan Z, Borthakur G, Kantarjian H, Garcia-Manero G. RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype. Br J Haematol 169(3):344-51, 2015. e-Pub 2015. PMID: 25612675.
- Yang H, Maddipoti S, Quesada A, Bohannan Z, Cabrero Calvo M, Colla S, Wei Y, Estecio M, Wierda W, Bueso-Ramos C, Garcia-Manero G. Analysis of class I and II histone deacetylase gene expression in human leukemia. Leuk Lymphoma 56(12):3426-33, 2015. e-Pub 2015. PMID: 25944469.
- Quintás-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 14(5):401-10, 2014. e-Pub 2014. PMID: 24875590.
- Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng QR, Fang Z, Nguyen M, Pierce S, Wei Y, Parmar S, Cortes J, Kantarjian H, Garcia-Manero G. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 28(6):1280-8, 2014. e-Pub 2014. PMID: 24270737.
- Gañán-Gómez I, Wei Y, Yang H, Pierce S, Bueso-Ramos C, Calin G, Boyano-Adánez Mdel C, García-Manero G. Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-κB activation and enhances erythroid differentiation arrest. PLoS One 9(4):e93404, 2014. e-Pub 2014. PMID: 24690917.
- Gañán-Gómez I, Wei Y, Yang H, Boyano-Adánez MC, García-Manero G. Oncogenic functions of the transcription factor Nrf2. Free Radic Biol Med 65:750-64, 2013. e-Pub 2013. PMID: 23820265.
- Wei Y, Chen R, Dimicoli S, Bueso-Ramos C, Neuberg D, Pierce S, Wang H, Yang H, Jia Y, Zheng H, Fang Z, Nguyen M, Ganan-Gomez I, Ebert B, Levine R, Kantarjian H, Garcia-Manero G. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. Leukemia 27(11):2177-86, 2013. e-Pub 2013. PMID: 23538751.
- Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia 27(10):2081-3, 2013. e-Pub 2013. PMID: 23774633.
- Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, Borthakur G, Estrov Z, O'Brien S, Mallo M, Wierda W, Pierce S, Wei Y, Sole F, Chen R, Kantarjian H, Garcia-Manero G. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol 88(10):831-7, 2013. e-Pub 2013. PMID: 23760779.
- DiNardo CD, Gharibyan V, Yang H, Wei Y, Pierce S, Kantarjian HM, Garcia-Manero G, Rytting M. Impact of aberrant DNA methylation patterns including CYP1B1 methylation in adolescents and young adults with acute lymphocytic leukemia. Am J Hematol 88(9):784-9, 2013. e-Pub 2013. PMID: 23757320.
- Wei Y, Dimicoli S, Bueso-Ramos C, Chen R, Yang H, Neuberg D, Pierce S, Jia Y, Zheng H, Wang H, Wang X, Nguyen M, Wang SA, Ebert B, Bejar R, Levine R, Abdel-Wahab O, Kleppe M, Ganan-Gomez I, Kantarjian H, Garcia-Manero G. Toll-like receptor alterations in myelodysplastic syndrome. Leukemia 27(9):1832-40, 2013. e-Pub 2013. PMID: 23765228.
- Attieh Y, Geng QR, Dinardo CD, Zheng H, Jia Y, Fang ZH, Gañán-Gómez I, Yang H, Wei Y, Kantarjian H, Garcia-Manero G. Low frequency of H3.3 mutations and upregulated DAXX expression in MDS. Blood 121(19):4009-11, 2013. e-Pub 2013. PMID: 23660862.
- Dimicoli S, Wei Y, Bueso-Ramos C, Yang H, Dinardo C, Jia Y, Zheng H, Fang Z, Nguyen M, Pierce S, Chen R, Wang H, Wu C, Garcia-Manero G. Overexpression of the Toll-Like Receptor (TLR) Signaling Adaptor MYD88, but Lack of Genetic Mutation, in Myelodysplastic Syndromes. PLoS One 8(8):e71120, 2013. e-Pub 2013. PMID: 23976989.
- Kuang SQ, Fang Z, Zweidler-McKay PA, Yang H, Wei Y, Gonzalez-Cervantes EA, Boumber Y, Garcia-Manero G. Epigenetic inactivation of notch-hes pathway in human B-cell acute lymphoblastic leukemia. PLoS One 8(4):e61807, 2013. e-Pub 2013. PMID: 23637910.
- Wei Y, Gañán-Gómez I, Salazar-Dimicoli S, McCay SL, Garcia-Manero G. Histone Methylation in myelodysplastic syndromes. Epigenomics 3(2):193-205, 2011. e-Pub 2011. PMID: 22122281.
- Yang H, Fang Z, Wei Y, Hu Y, Calin GA, Kantarjian HM, Garcia-Manero G. Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA. Am J Hematol 86(2):237-8, 2011. e-Pub 2011. PMID: 21264920.
- Hu Y, Lu W, Chen G, Zhang H, Jia Y, Wei Y, Yang H, Zhang W, Fiskus W, Bhalla K, Keating M, Huang P, Garcia-Manero G. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound {beta}-phenylethyl isothiocyanate. Blood 116(15):2732-41, 2010. e-Pub 2010. PMID: 20566897.
- Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Viallet J, O'Brien S, Garcia-Manero G. The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Autophagy 6(7):976-8, 2010. e-Pub 2010. PMID: 20729640.
- Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, Wei Y, Yang H, Keating MJ, Garcia-Manero G. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics 5(6):499-508, 2010. e-Pub 2010. PMID: 20484983.
- Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Tambaro FP, Viallet J, O'Brien S, Garcia-Manero G. The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res 16(15):3923-32, 2010. e-Pub 2010. PMID: 20538760.
- Tong WG, Wei Y, Stevenson W, Kuang SQ, Fang Z, Zhang M, Arts J, Garcia-Manero G. Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor. Leuk Res 34(2):221-8, 2010. e-Pub 2010. PMID: 19682743.
- Kuang SQ, Tong WG, Yang H, Lin W, Lee MK, Fang ZH, Wei Y, Jelinek J, Issa JP, Garcia-Manero G. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 22(8):1529-38, 2008. e-Pub 2008. PMID: 18528427.
- Miele A, Braastad CD, Holmes WF, Mitra P, Medina R, Xie R, Zaidi SK, Ye X, Wei Y, Harper JW, van Wijnen AJ, Stein JL, Stein GS. HiNF-P directly links the cyclin E/CDK2/p220NPAT pathway to histone H4 gene regulation at the G1/S phase cell cycle transition. Mol Cell Biol 25(14):6140-53, 2005. e-Pub 2005. PMID: 15988025.
- Ye X, Wei Y, Nalepa G, Harper JW. The cyclin E/Cdk2 substrate p220(NPAT) is required for S-phase entry, histone gene expression, and Cajal body maintenance in human somatic cells. Mol Cell Biol 23(23):8586-600, 2003. e-Pub 2003. PMID: 14612403.
- Mitra P, Xie RL, Medina R, Hovhannisyan H, Zaidi SK, Wei Y, Harper JW, Stein JL, van Wijnen AJ, Stein GS. Identification of HiNF-P, a key activator of cell cycle-controlled histone H4 genes at the onset of S phase. Mol Cell Biol 23(22):8110-23, 2003. e-Pub 2003. PMID: 14585971.
- Xu L, Wei Y, Reboul J, Vaglio P, Shin TH, Vidal M, Elledge SJ, Harper JW. BTB proteins are substrate-specific adaptors in an SCF-like modular ubiquitin ligase containing CUL-3. Nature 425(6955):316-21, 2003. e-Pub 2003. PMID: 13679922.
- Wei Y, Jin J, Harper JW. The cyclin E/Cdk2 substrate and Cajal body component p220(NPAT) activates histone transcription through a novel LisH-like domain. Mol Cell Biol 23(10):3669-80, 2003. e-Pub 2003. PMID: 12724424.
Review Articles
- Gañán-Gómez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS, Verma A, Steidl U, Garcia-Manero G. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leukemia 29(7):1458-69, 2015. e-Pub 2015. PMID: 25761935.
Abstracts
- Wei Y, Kanagal-Shamanna R, Zheng H, Lockyer P, Darbaniyan F, Do K, Garcia-Manero G. Downregulation of UBA1 in Myelodysplastic Syndrome. Blood, 2022. e-Pub 2022.
- Darbaniyan F, Class C, Montalban Bravo G, Kanagal-Shamanna R, Estecio M, Lu Y, Soltysiak KA, Chien KS, Yang H, Sasaki K, Ganan-Gomez I, Colla S, Do K, Garcia-Manero G, Wei Y. Transcriptomic Signitures of Azacitidine (AZA) and Decitabine (DAC) Resistance in MDS and CMML. Blood, 2021. e-Pub 2021.
- Wei Y, Garcia-Manero G, Zheng H, Jia Y, Bao N, Jiang S, Khoury JD, Class C, Colla S, and Bueso-Ramos CE. KDM6B Overexpression and TET2 Deficiency Cooperatively Drive Development of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-like Phenotype in Mice. Blood(134 (Supplement 1)):562-562, 2019. e-Pub 2019.
- Wei Y, Garcia-Manero G, Zheng H, Jia Y, Bao N, Jiang S, Khoury JD, Class C, Colla S, and Bueso-Ramos CE. KDM6B Overexpression and TET2 Deficiency Cooperatively Drive Development of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-like Phenotype in Mice. Blood(134 (Supplement 1)):562-562, 2019. e-Pub 2019.
- Wei Y, Garcia-Manero G, Zheng H, Jia Y, Bao N, Jiang S, Khoury JD, Class C, Colla S, and Bueso-Ramos CE. Overexpression of Histone Demethylase KDM6B in the Hematopoietic Compartment Promotes the Effect of Innate Immune Activation and Results in Myelodysplastic Syndrome (MDS)-like Phenotype in Mice. Blood 130(Suppl 1):50, 2017. e-Pub 2017.
- Wei Y, Garcia-Manero G, Zheng H, Jia Y, Bao N, Jiang S, Khoury JD, Class C, Colla S, and Bueso-Ramos CE. Overexpression of Histone Demethylase KDM6B in the Hematopoietic Compartment Promotes the Effect of Innate Immune Activation and Results in Myelodysplastic Syndrome (MDS)-like Phenotype in Mice. Blood 130(Suppl 1):50, 2017. e-Pub 2017.
- Chamseddine A, Cabrero M, Wei Y, Ganan-Gomez I, Colla S, Takahashi K, Yang H, Bohannan Z, Garcia-Manero G. PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Clinical Lymphoma, Myeloma, & Leukemia 16(Supplement):S67-S73, 2016. e-Pub 2016.
- Chamseddine A, Cabrero M, Wei Y, Ganan-Gomez I, Colla S, Takahashi K, Yang H, Bohannan Z, Garcia-Manero G. PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Clinical Lymphoma, Myeloma, & Leukemia 16(Supplement):S67-S73, 2016. e-Pub 2016.
- Yang H, Bohannan ZS, Fang Z, Ganan-Gómez I, Wei Y, Paradiso LJ, Iwamura H, and Garcia-Manero G. Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Acute Myeloid Leukemia. Blood 128(22):2756, 2016. e-Pub 2016.
- Garcia-Manero G, Montalban-Bravo G, Yang H, Wei Y, Alvarado Y, DiNardo CD, Daver NG, Konopleva M, Hearn KP, Miller R, Arbe-Barnes S, Mc Guirk P, Kearney T, Keogh B, Kantarjian HM, and Reilly M. A Clinical Study of OPN-305, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy. Blood 128(22):227, 2016. e-Pub 2016.
- Wei Y, Zheng H, Jia Y, Bao N, Jiang S, Colla S, Bueso-Ramos CE, Khoury JD, Bohannan ZS, and Garcia-Manero G. Overexpression of KDM6B, an Epigenetic and Innate Immune Regulator, Results in Hematopoietic Alterations of Mice Including Changes in Hematopoietic Stem Cells. Blood 128(22):3149, 2016. e-Pub 2016.
- Wei Y, Jia Y, Zheng H, Yang H, Bohannan ZS, Lee J, Zhao C, Bueso-Ramos CE, Chamseddine AN, Garcia-Manero G. Pharmacological Inhibition of Histone Demethylase JMJD3 Reduces Leukemia Cell Survival and Represses Production of the Cytokine CCL2 in MDS/AML. Blood 126(23):5219, 2015. e-Pub 2015.
- Chamseddine AN, Wei Y, Cabrero M, Ganan-Gomez I, Colla S, Takahashi K, Yang H, Estecio MR, Bohannan Z, Pierce S, Bueso-Ramos CE, Kantarjian HM, Jabbour E, Garcia-Manero G. PDE4 Differential Expression Is a Potential Prognostic Factor and a Therapeutic Target in Myelodysplastic Syndromes. Blood 126(23):5227, 2015. e-Pub 2015.
- Marchesini M, Ogoti Y, Ganan-Gomez I, Wei Y, Bueso-Ramos CE, Garcia-Manero G, DePinho RA, Colla S. Telomere Dysfunction-Induced DNA Damage Drives Hematopoietic Stem Cell Fate. Blood 126(23):1156, 2015. e-Pub 2015.
- Gañán-Gómez I, Ogoti Y, Marchesini M, Wei Y, Yang H, Jiang S, Bueso=Ramos CE, Garcia-Manero G, Colla S. Effect of Azacytidine on the Hematopoietic Stem and Progenitor Cell Compartments of MDS Mouse Models: Unveiling the Mechanisms of Remission and Relapse. Blood 126(23):2852, 2015. e-Pub 2015.
- Chamseddine AN, Cabrero M, Wei Y, Ganan-Gomez I, Colla S, Takahashi K, Yang H, Estecio MR, Bohannan Z, Pierce S, Bueso-Ramos CE, Kantarjian HM, Jabbour E, Garcia-Manero G. Expression Of Phosphodiesterase 4 (PDE4) In Myelodysplastic Syndromes (MDS) And Its Impact On Outcome: Result Of A Transcriptome Profiling Using RNA Sequencing From 43 Patients With MDS And Chronic Myelomonocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 15(Supplement 2):S45-S46, 2015. e-Pub 2015.
- Chamseddine AN, Cabrero M, Wei Y, Ganan-Gomez I, Colla S, Takahashi K, Yang H, Estecio MR, Bohannan Z, Pierce S, Bueso-Ramos CE, Kantarjian HM, Jabbour E, Garcia-Manero G. Expression Of Phosphodiesterase 4 (PDE4) In Myelodysplastic Syndromes (MDS) And Its Impact On Outcome: Result Of A Transcriptome Profiling Using RNA Sequencing From 43 Patients With MDS And Chronic Myelomonocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 15(Supplement 2):S45-S46, 2015. e-Pub 2015.
- Wei Y, Cabrero M, Jia Y, Zheng H, Yang H, Fang Z, Bohannan Z, Garcia-Manero, G. Underexpression of EZH2 in Myelodysplastic Syndromes. Clinical Lymphoma. Myeloma, and Leukemia 15(Supplement):S231, 2015. e-Pub 2015.
- Wei Y, Cabrero M, Jia Y, Zheng H, Yang H, Fang Z, Bohannan Z, Garcia-Manero, G. Underexpression of EZH2 in Myelodysplastic Syndromes. Clinical Lymphoma. Myeloma, and Leukemia 15(Supplement):S231, 2015. e-Pub 2015.
- Wei Y, Cabrero M, Jia Y, Zheng H, Yang H, Fang Z, Bohannan Z, Chen R, Wang H, Colla S, Wang X, Grcia-Manero G. Association Between Down-Regulation of EZH2 and Abnormal Karyotype, Response to Hypomethylation Treatment, and Patient Survival in Myelodysplastic Syndromes. Blood 124(21):3241, 2014. e-Pub 2014.
- Marchesini M, Storti P, Ogoti Y, D'Anca M, Nezi L, Wei Y, Yang H, Ong D, Neri A, Giuliani N, Garcia-Manero G, DePinho R, Colla S. ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Blood 124(21):30, 2014. e-Pub 2014.
- Colla S, Ong D, Ogoti Y, Marchesini M, Mistry N, Clise-Dwyer K, Storti P, Viale A, Wei Y, Giuliani N, Yang H, D'Anca M, Estecio MR, Liang H, Kantarjian H, Wang AY, Chin L, Bueso-Ramos CE, Garcia-Manero G, DePinho R. A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome. Blood 124(21):523, 2014. e-Pub 2014.
- Estecio MR, Maddipoti S, DiNardo CD, Yang H, Stevenson W, Bueso-Ramos CE, Pierce SR, Wei Y, Garcia-Manero. Association Between RUNX3 Hypermethylation and Acute Myeloid Leukemia Inv(16) Subtype. Blood 124(21):3548, 2014. e-Pub 2014.
- Wei Y, Verma A, Cabrero M, Jia Y, Zheng H, Fang Z, Yu Y, Colla S, Bohannan Z, Bowman RV, Boultwood J, Garcia-Manero G. Association Between Downregulation of POT1 Expression and Chromosome 7 Deletion, Response to Hypomethylation Agent Treatment, and Patient Survival in Myelodysplastic Syndromes. Blood 124(21):4663, 2014. e-Pub 2014.
- CiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju H, Yang H, Wei Y, Wierda WG, Bueso-Ramos CE, Patel K, Cortes JE, Ravandi F, Kantarjian H, Garcia-Manero G. A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood 124(21):164, 2014. e-Pub 2014.
- Quintás-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G. A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 14(5):401-410, 2014. e-Pub 2014.
- Yang H, Bueso-Ramos CE, DiNardo CD, Estecio MR, Davanlou M, Geng Q, Fang Z, Nguyen M, Pierce S, Wei Y, Parmar S, Cortes JE, Kantarjian HM, Garcia-Manero G. Expression Of Immune Checkpoints PD-L1, PD-L2, PD-1 and CTLA4 Predict For Prognosis and Resistance To Hypomethylating Agents (HMAs) In Myelodysplastic Syndromes (MDS). Blood 122(21):2767, 2013. e-Pub 2013.
- Wei Y, Jia Y, Zheng H, Yang H, Chen R, Wang H, Wang X, Garcia-Manero G. Assessment Of EZH2 Expression In CD34+ Bone Marrow Progenitor Cells Of Patients Of Myelodysplastic Syndromes (MDS). Blood 122(21):2805, 2013. e-Pub 2013.
- Wei Y, Jia Y, Zheng H, Yang H, Fang Z, Colla S, Garcia-Manero G. Down-Regulated Expression Of Protection Of Telomeres 1 (POT1) Gene In Bone Marrow Hematopoietic Progenitor Cell Compartment Has Prognostic Value In Myelodysplastic Syndromes (MDS). Blood 122(21):1511, 2013. e-Pub 2013.
- Ganan-Gomez I, Wei Y, Yang H, Boyano-Adanez MC, Garcia-Manero G. Overexpression Of Mir-125a In Bone Marrow CD34+ cells Of Patients With Myelodysplastic Syndrome Is Correlated To a Poor Prognosis and May Contribute To The Pathogenesis Of The Disease Through The Modulation Of NF-Kb Activation and Enhancement Of Differentiation Arrest. Blood 122(21):5206, 2013. e-Pub 2013.
- Fang J, Siu X, Barker B, Bolanos L, Wei Y, Garcia-Maanero G, Starczynowski DT. Disease-Relevant Expression Of TRAF6 In Mouse HSC Results In An MDS-Like Disease. Blood 122(21):101, 2013. e-Pub 2013.
- Wei Y, Bueso-Ramos CE, Yang H, Jia Y, Zheng H, Colla S, Nguyen M, Fernandez M, Kantarjian HM, Garcia-Manero G. Serum Amyloid Protein A 1 (hSAA1) Is Overexpressed in Myelodysplastic Syndromes and Potentially Mediates Toll-Like Receptor 2 Innate Immunity Signaling in CD34+ Hematopoietic Stem Cells. Blood 120(1703), 2012. e-Pub 2012.
- Yang H, Bueso-Ramos CE, Pierce SA, Wei Y, Zhihong F, Nguyen M, Fernandez M, Cardenas-Turanzas M, Kantarjian HM, Garcia-Manero G. Upregulation of Focal Adhesion Kinase, a Potential Therapeutic Target, in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). Blood 120(2827), 2012. e-Pub 2012.
- Wei Y, Chen R, Dimicoli S, Bueso-Ramos CE, Neuberg DS, Pierce SA, Yang H, Jia Y, Zheng H, Fang Z, Nguyen M, Fernandez M, Wang SA, Kantarjian HM, Garcia-Manero G. Deregulation of TLR2-JMJD3 Innate Immunity Signaling, Including a Rare TLR2 SNP As a Potential Somatic Mutation, in Myelodysplastic Syndromes (MDS). Blood 120(3810), 2012. e-Pub 2012.
- Yang H, Bueso-Ramos CE, Parmar S, Wei Y, Fang Z, Nguyen M, Fernandez M, Pierce SA, Geng Q, Kantarjian HM, Cortes JE, Garcia-Manero G. Induction of PD-1 and PD-1 Ligand Expression by Hypomethylating Agents (HMA) in Myelodysplastic Syndromes and Acute Myelogenous Leukemia Suggest a Role for T Cell Function in Clinical Resistance to HMAs. Blood 120(3810), 2012. e-Pub 2012.
- Attieh Y, Wei Y, Yang H, Jia Y, Zheng H, Fang Z, Kantarjian HM, Garcia-Manero. Low Frequency of Molecular Alterations of H3.3-Atrx-Daxx Chromatin Remodeling Component Genes in Myelodysplastic Syndromes (MDS). Blood 120(3844), 2012. e-Pub 2012.
- Dimicoli S, Wei Y, Chen R, Bueso-Ramos CE, Pierce SA, Yang H, Jia Y, Zheng H, Fang Z, Ganan-Gomez I, Nguyen M, Fernandez M, Kantarjian HM, Garcia-Manero G. Toll-Like Receptor (TLR) Signaling Adaptor Protein MYD88 in Myelodysplastic Syndromes (MDS). Blood 120(556), 2012. e-Pub 2012.
- Yang H, Bueso-Ramos CE, Pierce SA, Wei Y, Fang Z, Nguyen M, Fernandez M, Cardenas-Turanzas M, Kantarjian HM, Garcia-Manero G. Expression Profiles of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) in Myelodysplastic Syndromes (MDS): Level of MMP-9 Is Associated with Improved Prognosis in MDS Patients. Blood 120(3845), 2012. e-Pub 2012.
- Tambaro FP, Wierda WG, Pierce S, Yang H, Wei Y, Fang Z, Kantarjian HM, Garcia-Manero G. ROS Activation Independent From Iron Overload in MDS. Blood 118(2798), 2011. e-Pub 2011.
- Yang H, Fang Z, Wei Y, Hu Y, Calin G, Kantarjian HM, Garcia-Manero G. Levels of Mir-29b or Mir-101 Do Not Predict Response In Patients (pts) with Acute Myelogenous Leukemia (AML) Treated with the Combination of 5-Azacytidine, Valproic Acid and ATRA. Blood 116(11), 2010. e-Pub 2010.
- Wei Y, Chen R, Bueso-Ramos C, Yang H, Jia Y, Fang Z, Garcia-Manero G. Use of genome-wide CHIP-SeqSeq analysis allows identification of deregulated molecular pathways in myelodysplastic syndromes (MDS). CPRIT Innovations in Cancer Prevention and Research Conference:31, 2010. e-Pub 2010.
- Tambaro FP, Vigil C, Hu Y, Yang H, Fang Z, Jia JY, Wei Y, Kantarjian HM, Altucci L, Ferrara F, Garcia-Manero G. Levels of Nrf2 and Keap1 Are Associated with Poor Prognostic Features In Myelodysplastic Syndromes (MDS). Blood 116(11), 2010. e-Pub 2010.
- Wei Y, Calin G, Jia Y, Zheng H, McCay S, Yang H, Fang Z, Garcia-Manero G. Analysis of Regulatory miRNAs of Histone Demethylase JMJD3 In MDS CD34+ Hematoprogenitor Cells. Blood 116(11), 2010. e-Pub 2010.
- Wei Y, Chen R, Bueso-Ramos CE, Wang H, Song X, Wang J, Yao H, Nguyen M, Fernandez M, Yang H, Garcia-Manero G. Genome-Wide Chip-Seq Analysis of Histone Methylation Reveals Modulators of NF-{kappa}B signalling and the Histone Demethylase JMJD3 as Implicated in Disease Progression in Myelodysplastic Syndrome (MDS). Blood 114(11), 2009. e-Pub 2009.
- Tong W, Wei Y, Stevenson W, Kuang SQ, Arts J, Garcia-Manero G. Antileukemia Activity of JNJ-26481585, a Potent Second-Generation Histone Deacetylase Inhibitor. Blood 112(11), 2008. e-Pub 2008.
- Maddipoti SC, Bueso-Ramos C, Yang H, Fernandez M, Kuang S, Stevenson W, Wei Y, Pierce S, Garcia-Manero G. Epigenetic Silencing of the RUNX3 Gene by Promoter Hypermethylation in Patients with Myeloid Leukemia. Blood 112(11), 2008. e-Pub 2008.
- Wei Y, Kadia T, Tong W, O'Brien S, Viallet J, Garcia-Manero G. The Combination of a Histone Deacetylase (HDAC) Inhibitor with the BCL-2 Inhibitor GX15-070 Has Synergistic Antileukemia Effect by Inducing Both Apoptotic and Autophagic Pathways. Blood 112(11), 2008. e-Pub 2008.
Letters to the Editor
- Wei, Y, Zheng, H, Li, Z, Lockyer, P, Darbaniyan, F, Kanagal-Shamanna, R, Yang, H, Hammond, DE, Garcia-Manero, G. Downregulation of UBA1 expression in myelodysplastic neoplasm. Leukemia 38: 2284-2288, 2024.
Patient Reviews
CV information above last modified July 22, 2026